RxDoctor Payments Data

Justin Henne

Family · Killeen, TXNPI 1235688755

Payments from drug & device makers

$6,355in general payments, 2019–2025

Across 279 payments — averaging $22.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • AbbVie$328
  • Collegium Pharmaceutical, Inc.$328
  • Pfizer$234
  • Medtronic$203
  • Amgen$157
  • plus $656 from 13 others

What the payments were for

  • Food & beverage$6,29399%
  • Education$621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,355 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$167,923
Medicare patients
258
Services billed
2,463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl21$16,076
Buprenorphine62$15,941
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl78$12,330
Emgality PenGalcanezumab-Gnlm13$8,730
Gabapentin278$3,824
Pregabalin173$3,605
Lidocaine32$2,840
Tizanidine Hcl203$2,308
Cyclobenzaprine Hcl151$2,011
Buprenorphine Hcl62$1,739
Tramadol Hcl187$1,738
Acetaminophen-CodeineAcetaminophen With Codeine64$1,732
Baclofen94$1,443
Celecoxib61$1,390
Tramadol Hcl ErTramadol Hcl26$1,222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Buprenorphine Hcl$35$30,010202 claims
Collegium Pharmaceutical, Inc.Belbuca$328$16,07621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in Killeen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →